Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

被引：0
|
作者：
Enriqueta Albizua
Miguel Gallardo
Santiago Barrio
Inmaculada Rapado
Ana Jimenez
Rosa Ayala
Daniel Rueda
Beatriz Sanchez-Espiridion
Eulalia Puigdecanet
Blanca Espinet
Lourdes Florensa
Carles Besses
Joaquin Martinez-Lopez
机构：
[1] Hospital Universitario 12 de Octubre,Servicio de Hematología
[2] Servicio de Hematología,Laboratoris de Citologia Hematológica/Citogenética Molecular. Servei de Patologia, GRETNHE
[3] Hospital Virgen de la Salud,Servicio de Hematología
[4] Spanish National Cancer Research Centre (CNIO),undefined
[5] IMIM-Hospital del Mar,undefined
[6] IMIM-Hospital del Mar,undefined
来源：
Annals of Hematology | 2011年 / 90卷
关键词：
Polycythemia vera; Essential thrombocythemia; Gene expression profile; RT-PCR; Response to hydroxyurea; Src family kinase (SFK);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study investigates the differential gene expression profile of JAK2V617F-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2V617F-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
引用
收藏
页码：939 / 946
页数：7
相关论文
共 50 条
  • [1] Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
    Albizua, Enriqueta
    Gallardo, Miguel
    Barrio, Santiago
    Rapado, Inmaculada
    Jimenez, Ana
    Ayala, Rosa
    Rueda, Daniel
    Sanchez-Espiridion, Beatriz
    Puigdecanet, Eulalia
    Espinet, Blanca
    Florensa, Lourdes
    Besses, Carles
    Martinez-Lopez, Joaquin
    ANNALS OF HEMATOLOGY, 2011, 90 (08) : 939 - 946
  • [2] GENE EXPRESSION PROFILE IN JAK2 V617F POSITIVE POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA RELATED TO RESPONSE TO HYDROXYUREA TREATMENT
    Miguel, G.
    Santiago, S.
    Enriqueta, A.
    Inmaculada, I.
    Rosa, R.
    Jimenez, A.
    Daniel, D.
    Eulalia, E.
    Blanca, B.
    Lourdes, L.
    Carles, C.
    Joaquin, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 400 - 401
  • [3] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine, RL
    Wadleigh, M
    Cools, J
    Ebert, BL
    Wernig, G
    Huntly, BJP
    Boggon, TJ
    Wlodarska, L
    Clark, JJ
    Moore, S
    Adelsperger, J
    Koo, S
    Lee, JC
    Gabriel, S
    Mercher, T
    D'Andrea, A
    Fröhling, S
    Döhner, K
    Marynen, P
    Vandenberghe, P
    Mesa, RA
    Tefferi, A
    Griffin, JD
    Eck, MJ
    Sellers, WR
    Meyerson, M
    Golub, TR
    Lee, SJ
    Gilliland, DG
    CANCER CELL, 2005, 7 (04) : 387 - 397
  • [4] Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
    Barbui, Tiziano
    Thiele, Juergen
    Carobbio, Alessandra
    Guglielmelli, Paola
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : 588 - 590
  • [5] Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
    Antonioli, Elisabetta
    Carobbio, Alessandra
    Pieri, Lisa
    Pancrazzi, Alessandro
    Guglielmelli, Paola
    Delaini, Federica
    Ponziani, Vanessa
    Bartalucci, Niccolo
    Tozzi, Lorenzo
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1435 - 1438
  • [6] Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
    Guglielmelli, Paola
    Mora, Barbara
    Gesullo, Francesca
    Mannelli, Francesco
    Loscocco, Giuseppe Gaetano
    Signori, Leonardo
    Pessina, Chiara
    Colugnat, Ilaria
    Aquila, Raffaela
    Balliu, Manjola
    Maccari, Chiara
    Romagnoli, Simone
    Paoli, Chiara
    Nacca, Elena
    Fagiolo, Lorenzo
    Maffioli, Margherita
    Barbui, Tiziano
    Passamonti, Francesco
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1550 - 1559
  • [7] Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)
    Brodsky, I
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01): : 105 - 106
  • [8] JAK2 V617 ALLELE BURDEN AND THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
    Kalagiakou, E.
    Evmorfiadis, I.
    Hatzouli, M.
    Manioudaki, E.
    Kotsopoulou, M.
    Malegkou, S.
    Vallianatou, K.
    Triantafyllopoulou, I. -D.
    Samaridis, E.
    Dadiotis, L.
    Mitsouli, Ch.
    Belessi, C.
    Laoutaris, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 21 - 21
  • [9] A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
    Verstovsek, Srdan
    Courby, Stephane
    Griesshammer, Martin
    Mesa, Ruben A.
    Brachmann, Carrie Baker
    Kawashima, Jun
    Maltzman, Julia D.
    Shao, Lixin
    Xin, Yan
    Huang, Daniel
    Bajel, Ashish
    LEUKEMIA RESEARCH, 2017, 60 : 11 - 17
  • [10] Ropeginterferon Alfa-2b Blunts Hyperactive JAK2 Activity in Polycythemia Vera and Essential Thrombocythemia
    Song, Jihyun
    Prchal, Josef T.
    BLOOD, 2023, 142
12345